Chung Tae-Wook, Moon Sung-Kwon, Chang Young-Chae, Ko Jeong-Heon, Lee Young-Choon, Cho Gun, Kim Soo-Hyun, Kim Jong-Guk, Kim Cheorl-Ho
National Research Laboratory for Glycobiology and Department of Biochemistry and Molecular Biology, Dongguk University College of Oriental Medicine, Kyungju, Kyungbuk, Korea.
FASEB J. 2004 Nov;18(14):1670-81. doi: 10.1096/fj.04-2126com.
Our previous studies have clearly shown that the angiogenic enzymes, matrix metalloproteinase (MMP) -2/9, are directly involved in human hepatic tumorigenesis and metastasis and suggest that the MMP-2/9 inhibitors, which have dual inhibitory activities on enzyme activity and transcription, represent the best candidates for achieving tumor regression. Many anti-cancer drugs have strong cellular cytotoxicity and side effects, indicating that strong anti-cancer drugs that have no or minimal cytotoxicity and side effects need to be developed. The specific aim of the present study was to develop powerful anti-cancer drugs with specific tumor regression and anti-metastatic potential having the dual inhibitory activities of specific MMP-2 and -9 enzyme activities and gene transcription at the molecular level. Caffeic acid (CA), a strong and selective MMP-9 activity and transcription inhibitor, was isolated from the plant Euonymus alatus and its derivative, caffeic acid phenethyl ester (CAPE), was synthesized. CA and CAPE selectively inhibited MMP-2 and -9 but not -1, -3, -7, or cathepsin K. Treatment of HepG2 cells with CA (100 microg/mL) and CAPE (5 microg/mL) suppressed phorbol 12-myristate 13-acetate (PMA) -induced MMP-9 expression by inhibiting the function of NF-kappaB, but not AP-1. We confirmed that CA and CAPE suppressed the growth of HepG2 tumor xenografts in nude mice in vivo. The subcutaneous and oral administrations of CA and CAPE significantly reduced the liver metastasis. These results confirm the therapeutic potential of the compounds and suggest that the anti-metastatic and anti-tumor effects of CA and CAPE are mediated through the selective suppression of MMP-9 enzyme activity and transcriptional down-regulation by the dual inhibition of NF-kappaB as well as MMP-9 catalytic activity.
我们之前的研究清楚地表明,血管生成酶——基质金属蛋白酶(MMP)-2/9直接参与人类肝癌的发生和转移,并提示对酶活性和转录具有双重抑制活性的MMP-2/9抑制剂是实现肿瘤消退的最佳候选药物。许多抗癌药物具有很强的细胞毒性和副作用,这表明需要开发无或极小细胞毒性和副作用的强效抗癌药物。本研究的具体目的是开发具有特定肿瘤消退和抗转移潜力的强效抗癌药物,这些药物在分子水平上对特定的MMP-2和-9酶活性及基因转录具有双重抑制活性。从植物卫矛中分离出了具有强而选择性的MMP-9活性和转录抑制剂咖啡酸(CA),并合成了其衍生物咖啡酸苯乙酯(CAPE)。CA和CAPE选择性抑制MMP-2和-9,但不抑制-1、-3、-7或组织蛋白酶K。用CA(100μg/mL)和CAPE(5μg/mL)处理HepG2细胞可通过抑制NF-κB的功能而非AP-1来抑制佛波酯12-肉豆蔻酸酯13-乙酸酯(PMA)诱导的MMP-9表达。我们证实CA和CAPE在体内可抑制裸鼠中HepG2肿瘤异种移植的生长。CA和CAPE的皮下和口服给药显著减少了肝转移。这些结果证实了这些化合物的治疗潜力,并提示CA和CAPE的抗转移和抗肿瘤作用是通过对NF-κB以及MMP-9催化活性的双重抑制来选择性抑制MMP-9酶活性和转录下调介导的。